Literature DB >> 17347911

Phenylketonuria: dietary and therapeutic challenges.

M Giovannini1, E Verduci, E Salvatici, L Fiori, E Riva.   

Abstract

PKU subjects need special attention in the definition of optimal supplementation of nutrients, which may be insufficient in relation to the type of diet and may otherwise manifest symptoms of deficit. In particular, it is necessary to pay great attention to the long-chain polyunsaturated fatty acid (LC-PUFA) levels in relation to correct development of the central nervous system. On the basis of numerous beneficial effects currently known, a permanent supplementation with LC-PUFAs, in particular with docosahexaenoic acid, should be considered. Moreover, new formulas, Phe-free peptides, and 'modulated' amino acid preparations might help in preventing nutritional deficiencies and imbalances, with the ultimate aim of improving growth. New strategies--such as supply of tetrahydrobiopterin--need to be optimized in terms of targets, patients and expected outcomes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17347911     DOI: 10.1007/s10545-007-0552-8

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.750


  59 in total

Review 1.  Health benefits of docosahexaenoic acid (DHA)

Authors:  L A Horrocks; Y K Yeo
Journal:  Pharmacol Res       Date:  1999-09       Impact factor: 7.658

2.  Fish oil supplementation improves visual evoked potentials in children with phenylketonuria.

Authors:  S Beblo; H Reinhardt; A C Muntau; W Mueller-Felber; A A Roscher; B Koletzko
Journal:  Neurology       Date:  2001-10-23       Impact factor: 9.910

3.  Effects of long-chain polyunsaturated fatty acid supplementation on fatty acid status and visual function in treated children with hyperphenylalaninemia.

Authors:  C Agostoni; N Massetto; G Biasucci; A Rottoli; M Bonvissuto; M G Bruzzese; M Giovannini; E Riva
Journal:  J Pediatr       Date:  2000-10       Impact factor: 4.406

4.  Neurological differences between 9-year-old children fed breast-milk or formula-milk as babies.

Authors:  C I Lanting; V Fidler; M Huisman; B C Touwen; E R Boersma
Journal:  Lancet       Date:  1994-11-12       Impact factor: 79.321

Review 5.  The influence of mutations of enzyme activity and phenylalanine tolerance in phenylalanine hydroxylase deficiency.

Authors:  F Güttler; P Guldberg
Journal:  Eur J Pediatr       Date:  1996-07       Impact factor: 3.183

6.  Maternal docosahexaenoic acid supplementation during pregnancy and visual evoked potential development in term infants: a double blind, prospective, randomised trial.

Authors:  C A Malcolm; D L McCulloch; C Montgomery; A Shepherd; L T Weaver
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2003-09       Impact factor: 5.747

Review 7.  Phenylketonuria due to phenylalanine hydroxylase deficiency: an unfolding story. Medical Research Council Working Party on Phenylketonuria.

Authors: 
Journal:  BMJ       Date:  1993-01-09

8.  A randomized trial of long-chain polyunsaturated fatty acid supplementation in infants with phenylketonuria.

Authors:  Carlo Agostoni; Ann Harvie; Daphne L McCulloch; Colin Demellweek; Forrester Cockburn; Marcello Giovannini; Gordon Murray; R Angus Harkness; Enrica Riva
Journal:  Dev Med Child Neurol       Date:  2006-03       Impact factor: 5.449

9.  Physical growth of children treated for phenylketonuria.

Authors:  M A McBurnie; R A Kronmal; V E Schuett; R Koch; C G Azeng
Journal:  Ann Hum Biol       Date:  1991 Jul-Aug       Impact factor: 1.533

10.  The phenylalanine response curve in relation to growth and mental development in the first year of life.

Authors:  L W van der Schot; W H Doesburg; R C Sengers
Journal:  Acta Paediatr Suppl       Date:  1994-12
View more
  21 in total

1.  New insights in growth of phenylketonuric patients.

Authors:  María L Couce; Ipek Guler; Andrés Anca-Couce; Marta Lojo; Alicia Mirás; Rosaura Leis; Alejandro Pérez-Muñuzuri; José M Fraga; Francisco Gude
Journal:  Eur J Pediatr       Date:  2014-11-01       Impact factor: 3.183

Review 2.  Oxidative stress in phenylketonuria: what is the evidence?

Authors:  Graziela S Ribas; Angela Sitta; Moacir Wajner; Carmen R Vargas
Journal:  Cell Mol Neurobiol       Date:  2011-04-23       Impact factor: 5.046

3.  A Systematic Review of BH4 (Sapropterin) for the Adjuvant Treatment of Phenylketonuria.

Authors:  Mary Lou Lindegren; Shanthi Krishnaswami; Tyler Reimschisel; Christopher Fonnesbeck; Nila A Sathe; Melissa L McPheeters
Journal:  JIMD Rep       Date:  2012-07-29

Review 4.  Sapropterin dihydrochloride for phenylketonuria.

Authors:  Usha Rani Somaraju; Marcus Merrin
Journal:  Cochrane Database Syst Rev       Date:  2015-03-27

5.  Large neutral amino acids in daily practice.

Authors:  Kirsten Kiær Ahring
Journal:  J Inherit Metab Dis       Date:  2010-03-19       Impact factor: 4.982

6.  L-carnitine blood levels and oxidative stress in treated phenylketonuric patients.

Authors:  Angela Sitta; Alethéa G Barschak; Marion Deon; Jurema F de Mari; Amanda T Barden; Camila S Vanzin; Giovana B Biancini; Ida V D Schwartz; Moacir Wajner; Carmen R Vargas
Journal:  Cell Mol Neurobiol       Date:  2008-09-24       Impact factor: 5.046

7.  Dietary habits and metabolic control in adolescents and young adults with phenylketonuria: self-imposed protein restriction may be harmful.

Authors:  A M Das; K Goedecke; U Meyer; N Kanzelmeyer; S Koch; S Illsinger; T Lücke; H Hartmann; K Lange; H Lanfermann; L Hoy; X-Q Ding
Journal:  JIMD Rep       Date:  2013-11-13

8.  Estimating the probability of IQ impairment from blood phenylalanine for phenylketonuria patients: a hierarchical meta-analysis.

Authors:  Christopher J Fonnesbeck; Melissa L McPheeters; Shanthi Krishnaswami; Mary Louise Lindegren; Tyler Reimschisel
Journal:  J Inherit Metab Dis       Date:  2012-11-30       Impact factor: 4.982

9.  In vivo catecholaminergic metabolism in the medial prefrontal cortex of ENU2 mice: an investigation of the cortical dopamine deficit in phenylketonuria.

Authors:  Tiziana Pascucci; Giacomo Giacovazzo; Diego Andolina; David Conversi; Fabio Cruciani; Simona Cabib; Stefano Puglisi-Allegra
Journal:  J Inherit Metab Dis       Date:  2012-03-24       Impact factor: 4.982

10.  5-Hydroxytryptophan during critical postnatal period improves cognitive performances and promotes dendritic spine maturation in genetic mouse model of phenylketonuria.

Authors:  Diego Andolina; David Conversi; Simona Cabib; Antonio Trabalza; Rossella Ventura; Stefano Puglisi-Allegra; Tiziana Pascucci
Journal:  Int J Neuropsychopharmacol       Date:  2010-11-01       Impact factor: 5.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.